RadNet (RDNT) Posts Record Revenue But Profit Growth Lags
RadNet posted record second-quarter revenue of $622.7 million, up 25.0% year-over-year, but net income and adjusted earnings per share both declined despite raising full-year guidance.
Xpeng shares sink as weak delivery forecast overshadows $6.3 billion robot unit valuation
Xpeng shares fell over 9% in Hong Kong after the Chinese EV maker issued weaker-than-expected third-quarter delivery guidance, though its robotics unit secured a $6.3 billion valuation.
Marvell shares tumble 6% as outlook underwhelms despite 37% revenue growth
Marvell Technology shares declined 6% following second-quarter results that exceeded guidance, as its raised fiscal 2028 outlook of around $18 billion failed to satisfy investor expectations.
A Record Renewables Quarter Powers The Andersons (ANDE) Higher
The Andersons reported second-quarter net income of $57 million, or $1.65 per diluted share, driven primarily by record renewable fuels segment results and strong operational performance.
Central Garden & Pet (CENT) Raises Guidance Even As Sales Slide
Central Garden & Pet raised its full-year profit outlook despite reporting an 8% decline in net sales to $882 million for the fiscal third quarter, driven by margin expansion and a pending European acquisition.
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
Biohaven licensed its lead epilepsy drug opakalim to SK Biopharmaceuticals in a deal valued up to $795 million, providing $400 million in near-term cash to offset significant quarterly losses.